Why Bullish Analysts Still See Major Upside in Gossamer Bio (GOSS) After PROSERA Setback

Gossamer Bio remained successful absorption successful March 2026 aft its late-February Phase 3 PROSERA survey of seralutinib successful pulmonary arterial hypertension missed its superior endpoint, though the institution said it planned to conscionable with the U.S. Food and Drug Administration to sermon a imaginable way guardant and paused enrollment successful the SERANATA survey portion it reviewed the data.

Even aft cutting their terms targets, some Oppenheimer and H.C. Wainwright kept bullish ratings connected the stock. On March 5, Oppenheimer maintained its Outperform standing and lowered its people to $3 from $12. On March 6, H.C. Wainwright maintained its Buy standing and chopped its people to $5 from $10. Based connected Gossamer Bio’s caller stock terms of astir $0.37, Oppenheimer’s people inactive implied upside of much than 700%, portion H.C. Wainwright’s people implied upside of much than 1,200%.

Public summaries of the H.C. Wainwright update noted that expert Patrick Trucchio reduced the estimated probability of occurrence for seralutinib successful PAH to 50% from 70%. Even so, aboriginal reporting connected the firm’s presumption said the information inactive “demonstrate grounds of objective activity,” peculiarly successful heavy pretreated patients, and that “a way guardant whitethorn yet emerge,” though regulatory and superior uncertainty would apt stay an overhang.

Gossamer Bio, Inc. (NASDAQ:GOSS) is simply a clinical-stage biopharmaceutical institution processing therapies for pulmonary hypertension and different superior diseases.

While we admit the imaginable of GOSS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.